{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:33:36Z","timestamp":1786980816095,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012533","name":"Minia University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012533","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Homozygous Familial Hypercholesterolemia (HoFH) is a rare and life-threatening genetic disorder characterized by elevated low-density lipoprotein cholesterol (LDL-C) and early-onset atherosclerotic cardiovascular disease. Lomitapide, a microsomal triglyceride transfer protein (MTP) inhibitor, decreases LDL-C independent of LDL receptor function, providing an alternative treatment in this population. We aimed to evaluate the efficacy and safety of lomitapide in patients with HoFH through a systematic review and meta-analysis of available clinical evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A comprehensive search was conducted in PubMed, Scopus, and Web of Science through March 2025. Observational studies and clinical trials reporting on lipid profile changes and safety outcomes in HoFH patients receiving lomitapide were included. Outcomes were pooled using random-effects models, and heterogeneity was assessed using the I\n                      <jats:sup>2<\/jats:sup>\n                      statistic.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eight studies comprising both adult and pediatric patients (n\u2009=\u2009209) were included. Lomitapide significantly reduced LDL-C levels by 49.27%, total cholesterol by 46.05%, and apolipoprotein B by 51.01%. Reductions were also observed in triglycerides, VLDL-C, and non\u2013HDL-C. HDL-C remained relatively unchanged. Adverse events were mostly gastrointestinal, with a 14% discontinuation rate. The overall quality of studies ranged from fair to good.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Lomitapide demonstrates substantial efficacy in reducing LDL-C and other atherogenic lipids in HoFH patients, with an acceptable safety profile. These findings support its role as an adjunctive therapy in this population, though further randomized controlled trials are warranted to validate long-term safety and effectiveness.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10557-025-07764-4","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T07:34:15Z","timestamp":1756193655000},"page":"953-969","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Lomitapide, a Microsomal Triglyceride Transfer Protein Inhibitor, in Homozygous Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis of Efficacy and Safety"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9111-0392","authenticated-orcid":false,"given":"Mohamed","family":"Nasser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem E.","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed E.","family":"Haseeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Khalafalla","family":"Darwish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Hanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada A.","family":"Abdelaziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas Hussien","family":"Heiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman","family":"Shata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Salem","family":"Abdelkader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"7764_CR1","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","volume":"35","author":"M Cuchel","year":"2014","unstructured":"Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014;35:2146\u201357. https:\/\/doi.org\/10.1093\/eurheartj\/ehu274.","journal-title":"Eur Heart J"},{"key":"7764_CR2","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S0140-6736(21)02001-8","volume":"399","author":"TR Tromp","year":"2022","unstructured":"Tromp TR, Hartgers ML, Hovingh GK, et al. Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet. 2022;399:719\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(21)02001-8.","journal-title":"Lancet"},{"key":"7764_CR3","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"BG Nordestgaard","year":"2013","unstructured":"Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34:3478\u201390. https:\/\/doi.org\/10.1093\/eurheartj\/eht273.","journal-title":"Eur Heart J"},{"key":"7764_CR4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/s0022-3476(88)80289-0","volume":"113","author":"R Uauy","year":"1988","unstructured":"Uauy R, Vega GL, Grundy SM, Bilheimer DM. Lovastatin therapy in receptor-negative homozygous familial hypercholesterolemia: lack of effect on low-density lipoprotein concentrations or turnover. J Pediatr. 1988;113:387\u201392. https:\/\/doi.org\/10.1016\/s0022-3476(88)80289-0.","journal-title":"J Pediatr"},{"key":"7764_CR5","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/0021-9150(80)90124-0","volume":"35","author":"A Yamamoto","year":"1980","unstructured":"Yamamoto A, Sudo H, Endo A. Therapeutic effects of ML-236B in primary hypercholesterolemia. Atherosclerosis. 1980;35:259\u201366. https:\/\/doi.org\/10.1016\/0021-9150(80)90124-0.","journal-title":"Atherosclerosis"},{"key":"7764_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11883-002-0058-7","volume":"4","author":"AD Marais","year":"2002","unstructured":"Marais AD, Blom DJ, Firth JC. Statins in homozygous familial hypercholesterolemia. Curr Atheroscler Rep. 2002;4:19\u201325. https:\/\/doi.org\/10.1007\/s11883-002-0058-7.","journal-title":"Curr Atheroscler Rep"},{"key":"7764_CR7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/s0002-9149(96)00742-4","volume":"79","author":"MH Davidson","year":"1997","unstructured":"Davidson MH, Stein EA, Dujovne CA, et al. The efficacy and six-week tolerability of simvastatin 80 and 160 mg\/day. Am J Cardiol. 1997;79:38\u201342. https:\/\/doi.org\/10.1016\/s0002-9149(96)00742-4.","journal-title":"Am J Cardiol"},{"key":"7764_CR8","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0021-9150(97)00168-8","volume":"135","author":"FJ Raal","year":"1997","unstructured":"Raal FJ, Pilcher GJ, Illingworth DR, et al. Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia. Atherosclerosis. 1997;135:249\u201356. https:\/\/doi.org\/10.1016\/S0021-9150(97)00168-8.","journal-title":"Atherosclerosis"},{"key":"7764_CR9","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","volume":"44","author":"M Cuchel","year":"2023","unstructured":"Cuchel M, Raal FJ, Hegele RA, et al. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J. 2023;44:2277\u201391. https:\/\/doi.org\/10.1093\/eurheartj\/ehad197.","journal-title":"Eur Heart J"},{"key":"7764_CR10","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa2004215","volume":"383","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383:711\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2004215.","journal-title":"N Engl J Med"},{"key":"7764_CR11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","volume":"381","author":"M Cuchel","year":"2013","unstructured":"Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013;381:40\u20136. https:\/\/doi.org\/10.1016\/S0140-6736(12)61731-0.","journal-title":"Lancet"},{"key":"7764_CR12","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jacl.2011.04.003","volume":"5","author":"AC Goldberg","year":"2011","unstructured":"Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5:S1-8. https:\/\/doi.org\/10.1016\/j.jacl.2011.04.003.","journal-title":"J Clin Lipidol"},{"key":"7764_CR13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1743-7075-9-14","volume":"9","author":"MM Hussain","year":"2012","unstructured":"Hussain MM, Rava P, Walsh M, Rana M, Iqbal J. Multiple functions of microsomal triglyceride transfer protein. Nutr Metab (Lond). 2012;9:14. https:\/\/doi.org\/10.1186\/1743-7075-9-14.","journal-title":"Nutr Metab (Lond)"},{"key":"7764_CR14","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1146\/annurev.nutr.20.1.663","volume":"20","author":"N Berriot-Varoqueaux","year":"2000","unstructured":"Berriot-Varoqueaux N, Aggerbeck LP, Samson-Bouma M, Wetterau JR. The role of the microsomal triglygeride transfer protein in abetalipoproteinemia. Annu Rev Nutr. 2000;20:663\u201397. https:\/\/doi.org\/10.1146\/annurev.nutr.20.1.663.","journal-title":"Annu Rev Nutr"},{"key":"7764_CR15","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/S2213-8587(24)00233-X","volume":"12","author":"L Masana","year":"2024","unstructured":"Masana L, Zambon A, Schmitt CP, et al. Lomitapide for the treatment of paediatric patients with homozygous familial hypercholesterolaemia (APH-19): results from the efficacy phase of an open-label, multicentre, phase 3 study. Lancet Diabetes Endocrinol. 2024;12:880\u20139. https:\/\/doi.org\/10.1016\/S2213-8587(24)00233-X.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"7764_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000100","volume":"6","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6: e1000100. https:\/\/doi.org\/10.1371\/journal.pmed.1000100.","journal-title":"PLoS Med"},{"key":"7764_CR17","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5:210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4.","journal-title":"Syst Rev"},{"key":"7764_CR18","unstructured":"Study Quality Assessment Tools | NHLBI, NIH n.d. https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools (accessed April 15, 2025)."},{"key":"7764_CR19","unstructured":"R Core Team (2023). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https:\/\/www.R-project.org\/. n.d."},{"key":"7764_CR20","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/2047487319870007","volume":"27","author":"G Kolovou","year":"2020","unstructured":"Kolovou G, Diakoumakou O, Kolovou V, et al. Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia. Eur J Prev Cardiol. 2020;27:157\u201365. https:\/\/doi.org\/10.1177\/2047487319870007.","journal-title":"Eur J Prev Cardiol"},{"key":"7764_CR21","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1056\/NEJMoa061189","volume":"356","author":"M Cuchel","year":"2007","unstructured":"Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007;356:148\u201356. https:\/\/doi.org\/10.1056\/NEJMoa061189.","journal-title":"N Engl J Med"},{"key":"7764_CR22","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1007\/s12325-017-0531-x","volume":"34","author":"L D\u2019Erasmo","year":"2017","unstructured":"D\u2019Erasmo L, Cefal\u00f9 AB, Noto D, et al. Efficacy of lomitapide in the treatment of familial homozygous hypercholesterolemia: results of a real-world clinical experience in Italy. Adv Ther. 2017;34:1200\u201310. https:\/\/doi.org\/10.1007\/s12325-017-0531-x.","journal-title":"Adv Ther"},{"key":"7764_CR23","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1093\/eurjpc\/zwab229","volume":"29","author":"L D\u2019Erasmo","year":"2022","unstructured":"D\u2019Erasmo L, Steward K, Cefal\u00f9 AB, et al. Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study. Eur J Prev Cardiol. 2022;29:832\u201341. https:\/\/doi.org\/10.1093\/eurjpc\/zwab229.","journal-title":"Eur J Prev Cardiol"},{"key":"7764_CR24","doi-asserted-by":"publisher","first-page":"402","DOI":"10.5551\/jat.38216","volume":"24","author":"M Harada-Shiba","year":"2017","unstructured":"Harada-Shiba M, Ikewaki K, Nohara A, et al. Efficacy and safety of lomitapide in Japanese patients with homozygous familial hypercholesterolemia. J Atheroscler Thromb. 2017;24:402\u201311. https:\/\/doi.org\/10.5551\/jat.38216.","journal-title":"J Atheroscler Thromb"},{"key":"7764_CR25","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.jacl.2020.08.006","volume":"14","author":"JA Underberg","year":"2020","unstructured":"Underberg JA, Cannon CP, Larrey D, Makris L, Blom D, Phillips H. Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: five-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER). J Clin Lipidol. 2020;14:807\u201317. https:\/\/doi.org\/10.1016\/j.jacl.2020.08.006.","journal-title":"J Clin Lipidol"},{"key":"7764_CR26","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1001\/jamacardio.2019.3780","volume":"4","author":"AD Sniderman","year":"2019","unstructured":"Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol. 2019;4:1287\u201395. https:\/\/doi.org\/10.1001\/jamacardio.2019.3780.","journal-title":"JAMA Cardiol"},{"key":"7764_CR27","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1161\/CIRCULATIONAHA.119.041998","volume":"140","author":"NA Marston","year":"2019","unstructured":"Marston NA, Giugliano RP, Im K, et al. Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes: a systematic review and meta-regression analysis of randomized controlled trials. Circulation. 2019;140:1308\u201317. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.041998.","journal-title":"Circulation"},{"key":"7764_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12929-016-0256-1","volume":"23","author":"R Henderson","year":"2016","unstructured":"Henderson R, O\u2019Kane M, McGilligan V, Watterson S. The genetics and screening of familial hypercholesterolaemia. J Biomed Sci. 2016;23:39. https:\/\/doi.org\/10.1186\/s12929-016-0256-1.","journal-title":"J Biomed Sci"},{"key":"7764_CR29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/1755-5922.12105","volume":"33","author":"G Kolovou","year":"2015","unstructured":"Kolovou G, Vasiliadis I, Gontoras N, Kolovou V, Hatzigeorgiou G. Microsomal transfer protein inhibitors, new approach for treatment of familial hypercholesterolemia, review of the literature, original findings, and clinical significance. Cardiovasc Ther. 2015;33:71\u20138. https:\/\/doi.org\/10.1111\/1755-5922.12105.","journal-title":"Cardiovasc Ther"},{"key":"7764_CR30","unstructured":"Medscape Registration n.d. https:\/\/www.medscape.com\/viewarticle\/821019?form=fpf (accessed April 2, 2025)."},{"key":"7764_CR31","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jacc.2020.05.033","volume":"76","author":"GR Thompson","year":"2020","unstructured":"Thompson GR. PCSK9 inhibitors for homozygous familial hypercholesterolemia. J Am Coll Cardiol. 2020;76:143\u20135. https:\/\/doi.org\/10.1016\/j.jacc.2020.05.033.","journal-title":"J Am Coll Cardiol"},{"key":"7764_CR32","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1177\/2047487317730473","volume":"24","author":"R Leipold","year":"2017","unstructured":"Leipold R, Raal F, Ishak J, Hovingh K, Phillips H. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: a modelling analysis. Eur J Prev Cardiol. 2017;24:1843\u201350. https:\/\/doi.org\/10.1177\/2047487317730473.","journal-title":"Eur J Prev Cardiol"},{"key":"7764_CR33","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13023-018-0841-3","volume":"13","author":"DJ Blom","year":"2018","unstructured":"Blom DJ, Cuchel M, Ager M, Phillips H. Target achievement and cardiovascular event rates with Lomitapide in homozygous familial hypercholesterolaemia. Orphanet J Rare Dis. 2018;13:96. https:\/\/doi.org\/10.1186\/s13023-018-0841-3.","journal-title":"Orphanet J Rare Dis"},{"key":"7764_CR34","doi-asserted-by":"publisher","first-page":"e304","DOI":"10.1161\/ATV.0000000000000177","volume":"44","author":"E Gianos","year":"2024","unstructured":"Gianos E, Duell PB, Toth PP, et al. Lipoprotein apheresis: utility, outcomes, and implementation in clinical practice: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2024;44:e304\u201321. https:\/\/doi.org\/10.1161\/ATV.0000000000000177.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"7764_CR35","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1186\/s13023-021-01999-8","volume":"16","author":"L D\u2019Erasmo","year":"2021","unstructured":"D\u2019Erasmo L, Gallo A, Cefal\u00f9 AB, et al. Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey. Orphanet J Rare Dis. 2021;16:381. https:\/\/doi.org\/10.1186\/s13023-021-01999-8.","journal-title":"Orphanet J Rare Dis"},{"key":"7764_CR36","unstructured":"Juxtapid (lomitapide) dosing, indications, interactions, adverse effects, and more n.d. https:\/\/reference.medscape.com\/drug\/juxtapid-lomitapide-999804#4 (accessed March 30, 2025)."},{"key":"7764_CR37","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1161\/CIRCULATIONAHA.117.028208","volume":"136","author":"DJ Blom","year":"2017","unstructured":"Blom DJ, Averna MR, Meagher EA, et al. Long-term efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in patients with homozygous familial hypercholesterolemia. Circulation. 2017;136:332\u20135. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.028208.","journal-title":"Circulation"},{"key":"7764_CR38","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1007\/s12325-019-00985-8","volume":"36","author":"T Ben-Omran","year":"2019","unstructured":"Ben-Omran T, Masana L, Kolovou G, et al. Real-world outcomes with lomitapide use in paediatric patients with homozygous familial hypercholesterolaemia. Adv Ther. 2019;36:1786\u2013811. https:\/\/doi.org\/10.1007\/s12325-019-00985-8.","journal-title":"Adv Ther"},{"key":"7764_CR39","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/00041433-199706000-00002","volume":"8","author":"DA Gordon","year":"1997","unstructured":"Gordon DA. Recent advances in elucidating the role of the microsomal triglyceride transfer protein in apolipoprotein B lipoprotein assembly. Curr Opin Lipidol. 1997;8:131\u20137. https:\/\/doi.org\/10.1097\/00041433-199706000-00002.","journal-title":"Curr Opin Lipidol"},{"key":"7764_CR40","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1186\/s13023-024-03374-9","volume":"19","author":"P Suppressa","year":"2024","unstructured":"Suppressa P, Coppola C, Cocco V, O\u2019Brien S. Long-term effectiveness and safety of lomitapide in patients with homozygous familial hypercholesterolemia: an observational case series. Orphanet J Rare Dis. 2024;19:370. https:\/\/doi.org\/10.1186\/s13023-024-03374-9.","journal-title":"Orphanet J Rare Dis"},{"key":"7764_CR41","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1001\/jamacardio.2023.5597","volume":"9","author":"JWCM Mulder","year":"2024","unstructured":"Mulder JWCM, Tromp TR, Al-Khnifsawi M, et al. Sex differences in diagnosis, treatment, and cardiovascular outcomes in homozygous familial hypercholesterolemia. JAMA Cardiol. 2024;9:313\u201322. https:\/\/doi.org\/10.1001\/jamacardio.2023.5597.","journal-title":"JAMA Cardiol"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07764-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-025-07764-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07764-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:21:23Z","timestamp":1778649683000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-025-07764-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7764"],"URL":"https:\/\/doi.org\/10.1007\/s10557-025-07764-4","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,26]]},"assertion":[{"value":"12 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Our manuscript was not applied to human beings and thus requires no ethical approval.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate statement"}}]}}